Forecasted sales of top hemophilia products worldwide 2026

In 2026, the hemophilia drug Hemlibra is forecasted to generate 5.6 billion U.S. dollars worldwide in sales revenue, while NovoSeven is forecasted to generate 796 million U.S. dollars in sales revenue. This statistic illustrates the forecasted sales of top hemophilia products worldwide in 2026.

至2026年，血液凝固病药物Hemlibra预计将实现全球销售额56亿美元，而NovoSeven的全球销售额预计将达到7.96亿美元。此统计数据描绘了2026年全球主要血液凝固病产品的预测销售额。